Pfizer Inc. $PFE Holdings Raised by Private Wealth Asset Management LLC

Private Wealth Asset Management LLC lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 171.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,029 shares of the biopharmaceutical company’s stock after acquiring an additional 57,542 shares during the quarter. Private Wealth Asset Management LLC’s holdings in Pfizer were worth $2,675,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in shares of Pfizer in the 2nd quarter worth approximately $1,049,602,000. BlackRock Inc. increased its holdings in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the period. Nykredit A S purchased a new position in Pfizer during the second quarter valued at approximately $205,774,000. Assenagon Asset Management S.A. increased its holdings in Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after buying an additional 5,829,204 shares during the period. Finally, State Street Corp raised its stake in Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after buying an additional 5,501,032 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.5%

Pfizer stock opened at $27.41 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42. The stock has a market cap of $156.25 billion, a PE ratio of 39.16, a price-to-earnings-growth ratio of 1.90 and a beta of 0.31. The stock has a 50-day moving average of $28.82 and a two-hundred day moving average of $27.03. Pfizer Inc. has a one year low of $23.62 and a one year high of $31.44.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the firm earned $0.87 earnings per share. The company’s revenue was down .4% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 3.04 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is 245.71%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Sanford C. Bernstein restated a “market perform” rating and set a $29.00 target price on shares of Pfizer in a report on Thursday, November 12th. UBS Group lifted their price target on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. DZ Bank lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. FBN Securities set a $34.00 price target on Pfizer in a research report on Friday, November 6th. Finally, Weiss Ratings upgraded Pfizer from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $30.32.

View Our Latest Research Report on Pfizer

Pfizer News Roundup

Investors following PFE have been watching these news items:

  • Positive Sentiment: Pfizer secured exclusive rights outside Greater China to Starna Therapeutics’ three investigational in vivo CAR-T programs for autoimmune diseases. The agreement includes a $330 million upfront payment and up to $2.3 billion in potential milestones, adding a novel approach to Pfizer’s pipeline. Because the programs are preclinical, any commercial payoff is likely years away and uncertain. Article: Pfizer Secures Exclusive Rights To In Vivo CAR T Autoimmune Programs
  • Neutral Sentiment: Pfizer also reported updates to clinical studies, including an RSV booster study in older adults and a Phase 3 study of berobenatide. The entries provide no trial results, so they offer limited evidence of near-term commercial impact. Article: Pfizer Advances RSV Booster Study in Older Adults
  • Negative Sentiment: Technical indicators cited in a market update showed weak near-term momentum, with daily signals at “Strong Sell” and hourly signals at “Sell.” That may weigh on sentiment even as Pfizer pursues pipeline growth. Article: Pfizer near-term support and resistance levels

About Pfizer

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.